阿托伐他汀钙制剂的开发以及体外和体内药代动力学相关性(IVIVC)与使用soluplus和羟丙基甲基纤维素的优化

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
Ch. Taraka Ramarao, Palepu Pavani
{"title":"阿托伐他汀钙制剂的开发以及体外和体内药代动力学相关性(IVIVC)与使用soluplus和羟丙基甲基纤维素的优化","authors":"Ch. Taraka Ramarao, Palepu Pavani","doi":"10.4103/epj.epj_43_22","DOIUrl":null,"url":null,"abstract":"Objectives The goal of this study was to evaluate different proportions of solid dispersions and formulations by employing various carriers in order to improve solubility of poorly soluble atorvastatin calcium. Materials and methods Solid dispersions can be created using the Solvent Evaporation technique. In comparison to pure drug, (Hydroxy propyl methyl cellulose) HPMC (1:1) indicated as (Solid dispersion) SD1, HPMC E5 (1:2), HPMC E5 (1:4), HPMC (1:1.5) designated as SD2, SD3, SD4, drug caffeine (1:0.5) and caffeine (1:1), denoted as SD5, SD6. The Design Expert software used to 2 level factorial design, the three independent components of X1: are ratios of solid dispersion equivalent (drug:HPMC:soluplus), X2:Superdisintegrant (Primellose), and X3:Surfactant (Sodium lauryl sulphate) was used to do analysis of variance (ANOVA), 3D surface plots, counter plots, optimization, and desirability. Fourier-transform infrared spectroscopy was used to investigate drug-excipient compatibility. Marketed tablets (uncoated tablets manufactured by ‘Revat Laboratories limited) with optimized tablet composition were used in the comparative trials (A2) and Pharmacokinetics. Results and discussion The solid dispersion approach greatly increased the amount of atorvastatin calcium released. The values of f1 and f2 were determined to be 1.89 and 77.78, respectively, and the dissolution profiles of the optimized formulation (A2) and the market tablet were found to be significance. The optimized formula did better on the desirability level (0.975), indicating that it was a good fit. To determine dose bioavailability and to see if there is an in-vitro-in-vivo link. Conclusion The formulations were successfully developed using factorial design, and can be further used for oral delivery of antilipidemic agents is atorvastatin calcium. The model’s predictability and validity were demonstrated when the experimental values matched the expected values. The in vitro-in vivo correlation was good in pharmacokinetic experiments, indicating a significant improvement.","PeriodicalId":11568,"journal":{"name":"Egyptian Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atorvastatin calcium formulation development followed by pharmacokinetic with in vitro and in vivo correlation (IVIVC) with employing soluplus and hydroxy propyl methyl cellulose with optimization\",\"authors\":\"Ch. Taraka Ramarao, Palepu Pavani\",\"doi\":\"10.4103/epj.epj_43_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives The goal of this study was to evaluate different proportions of solid dispersions and formulations by employing various carriers in order to improve solubility of poorly soluble atorvastatin calcium. Materials and methods Solid dispersions can be created using the Solvent Evaporation technique. In comparison to pure drug, (Hydroxy propyl methyl cellulose) HPMC (1:1) indicated as (Solid dispersion) SD1, HPMC E5 (1:2), HPMC E5 (1:4), HPMC (1:1.5) designated as SD2, SD3, SD4, drug caffeine (1:0.5) and caffeine (1:1), denoted as SD5, SD6. The Design Expert software used to 2 level factorial design, the three independent components of X1: are ratios of solid dispersion equivalent (drug:HPMC:soluplus), X2:Superdisintegrant (Primellose), and X3:Surfactant (Sodium lauryl sulphate) was used to do analysis of variance (ANOVA), 3D surface plots, counter plots, optimization, and desirability. Fourier-transform infrared spectroscopy was used to investigate drug-excipient compatibility. Marketed tablets (uncoated tablets manufactured by ‘Revat Laboratories limited) with optimized tablet composition were used in the comparative trials (A2) and Pharmacokinetics. Results and discussion The solid dispersion approach greatly increased the amount of atorvastatin calcium released. The values of f1 and f2 were determined to be 1.89 and 77.78, respectively, and the dissolution profiles of the optimized formulation (A2) and the market tablet were found to be significance. The optimized formula did better on the desirability level (0.975), indicating that it was a good fit. To determine dose bioavailability and to see if there is an in-vitro-in-vivo link. Conclusion The formulations were successfully developed using factorial design, and can be further used for oral delivery of antilipidemic agents is atorvastatin calcium. The model’s predictability and validity were demonstrated when the experimental values matched the expected values. The in vitro-in vivo correlation was good in pharmacokinetic experiments, indicating a significant improvement.\",\"PeriodicalId\":11568,\"journal\":{\"name\":\"Egyptian Pharmaceutical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Egyptian Pharmaceutical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/epj.epj_43_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/epj.epj_43_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的研究不同载体配比的固体分散体和配方,以提高难溶性阿托伐他汀钙的溶解度。材料和方法固体分散体可以用溶剂蒸发技术制造。与纯药物相比,(羟基丙基甲基纤维素)HPMC(1:1)表示(固体分散体)SD1, HPMC E5 (1:2), HPMC E5 (1:4), HPMC(1:1.5)表示SD2, SD3, SD4,药物咖啡因(1:0.5)和咖啡因(1:1)表示SD5, SD6。采用Design Expert软件进行2水平析因设计,X1:固体分散等效比(药物:HPMC:soluplus), X2:超崩解剂(Primellose), X3:表面活性剂(十二烷基硫酸钠)的三个独立分量分别进行方差分析(ANOVA)、三维曲面图、反图、优化和可取性分析。采用傅里叶变换红外光谱法研究药物与辅料的配伍性。采用优化片剂组成的市售片剂(由Revat Laboratories limited生产的无包衣片剂)进行对比试验(A2)和药代动力学研究。结果与讨论固体分散法大大增加了阿托伐他汀钙的释放量。f1和f2分别为1.89和77.78,优化处方(A2)与市售片剂的溶出度曲线具有显著性。优化后的公式在理想度水平(0.975)上表现较好,表明拟合较好。以确定剂量的生物利用度,并看看是否有体外体内的联系。结论采用析因设计成功研制了复方阿托伐他汀钙,可进一步用于口服给药。当实验值与期望值吻合时,验证了模型的可预测性和有效性。在药代动力学实验中,其体内外相关性良好,有明显改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Atorvastatin calcium formulation development followed by pharmacokinetic with in vitro and in vivo correlation (IVIVC) with employing soluplus and hydroxy propyl methyl cellulose with optimization
Objectives The goal of this study was to evaluate different proportions of solid dispersions and formulations by employing various carriers in order to improve solubility of poorly soluble atorvastatin calcium. Materials and methods Solid dispersions can be created using the Solvent Evaporation technique. In comparison to pure drug, (Hydroxy propyl methyl cellulose) HPMC (1:1) indicated as (Solid dispersion) SD1, HPMC E5 (1:2), HPMC E5 (1:4), HPMC (1:1.5) designated as SD2, SD3, SD4, drug caffeine (1:0.5) and caffeine (1:1), denoted as SD5, SD6. The Design Expert software used to 2 level factorial design, the three independent components of X1: are ratios of solid dispersion equivalent (drug:HPMC:soluplus), X2:Superdisintegrant (Primellose), and X3:Surfactant (Sodium lauryl sulphate) was used to do analysis of variance (ANOVA), 3D surface plots, counter plots, optimization, and desirability. Fourier-transform infrared spectroscopy was used to investigate drug-excipient compatibility. Marketed tablets (uncoated tablets manufactured by ‘Revat Laboratories limited) with optimized tablet composition were used in the comparative trials (A2) and Pharmacokinetics. Results and discussion The solid dispersion approach greatly increased the amount of atorvastatin calcium released. The values of f1 and f2 were determined to be 1.89 and 77.78, respectively, and the dissolution profiles of the optimized formulation (A2) and the market tablet were found to be significance. The optimized formula did better on the desirability level (0.975), indicating that it was a good fit. To determine dose bioavailability and to see if there is an in-vitro-in-vivo link. Conclusion The formulations were successfully developed using factorial design, and can be further used for oral delivery of antilipidemic agents is atorvastatin calcium. The model’s predictability and validity were demonstrated when the experimental values matched the expected values. The in vitro-in vivo correlation was good in pharmacokinetic experiments, indicating a significant improvement.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Egyptian Pharmaceutical Journal
Egyptian Pharmaceutical Journal PHARMACOLOGY & PHARMACY-
CiteScore
1.10
自引率
0.00%
发文量
37
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信